Drugs / Cashew
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03504774 | Jul 2019 → Jan 2023 | food allergy | Sayantani B. Sindher | Terminated | No outcome recorded Stop: Enrollment |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03881696 | Jul 2019 → Mar 2023 | food allergy | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cashew | “Multi-allergen OIT will be any of the following drug products: peanut, milk, egg, wheat, cashew, hazelnut, and walnut (all food protein flours).” NCT03881696 ↗ |
| Route | Oral | “Using Food Allergen Oral Immunotherapy for Shrimp or Cashew Allergies” NCT03504774 ↗ |